Review of the Current Clinical Evidence for Transcatheter Tricuspid Valve Therapies

Within the last 24 months, I have had financial relationship(s) with the ineligible company or companies listed below:

• Equity/Stock(s)/Options - Dura Biotech; Thubrikar Aortic Valve Inc; MicroInterventional Devices; Supira
• Consultant Fee/Honoraria/Speaker's Bureau - Meril Lifesciences; JenaValve; Admedus (Equity as well)
• Grant Support/Research Contract - Edwards Lifesciences; Abbott Vascular; Medtronic; Boston Scientific Corporation; St. Jude Medical